AI assistant
Bure Equity — Interim / Quarterly Report 2022
Feb 23, 2023
2899_10-k_2023-02-23_6643dae6-34ea-4838-9889-3d80a6a2fecd.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer

Year-end report 2022
Interim period January – December 2022
- Net asset value was SEK 196.3 per share compared to SEK 323.2 at the beginning of the year, equivalent to a decrease of 39.2 per cent.
- Bure's net asset value was SEK 14,559M compared to SEK 23,964M at the beginning of the year.
- Total return on the Bure share was -43.1 per cent compared to SIX Return Index that fell 22.8 per cent.
- Group earnings after tax amounted to SEK -9,235M (6,362). Earnings per share amounted to SEK -124.7 (85.7).
Interim period October – December 2022
• Net asset value was SEK 196.3 per share compared to SEK 163.7 at the beginning of the quarter, which is equivalent to an increase of 19.9 per cent.
Events after the end of the period
- Net asset value amounted to 215.5 per share on 22 February 2023, equivalent to an increase of 9.7 per cent since the beginning of the year.
- The board proposes to the annual general meeting an ordinary dividend of SEK 2.25 per share (2.25).
- Bure subscribed for 1,123,595 shares in Ovzon's rights issue for SEK 50M. The issue is planned to be conducted following a decision at an extraordinary general meeting of Ovzon on the 3 March 2023.
Henrik Blomquist
CEO Bure Equity AB

2022 will be remembered as one of the worst stock market years in two decades. War in Europe, spiralling interest rates, rampant inflation, skyhigh electricity prices, fluctuating currencies, and China closed by covid. Overall, these external factors caused the Stockholm stock exchange to fall 22.7 per cent in 2022. Bure's net asset value per share decreased -39.2 per cent. The stock market decline was particularly pronounced for many growth companies. Several of Bure's portfolio companies can be included in this category. The value trend in all listed portfolio companies was negative for the year and our core holding Vitrolife lost -66.8 per cent. However, in September we saw a turnaround. In the fourth quarter, Bure's net asset value per share increased 19.9 per cent compared to the SIX RX that increased 11.3 per cent.
The situation was challenging on a macro level and for stock markets in 2022. However, our portfolio companies performed well. Mycronic broke sales records and ended the year with a record-breaking order intake. Xvivo grew organically by 30 per cent and BioLamina by 78 per cent. Allgon improved its EBIT margin to just over 15 per cent and ScandiNova doubled its operating profit. Vitrolife also presented a strong report. The transition period following the acquisition of Igenomix formed the basis for, among other things, this year's improvement in margin and strong cash flow.
It is a relief to leave 2022 behind us, even though many concerns persist in 2023. Economic growth will probably continue to be weak, but the likelihood of a severe recession has decreased. Interest rates are still moving upwards but inflation has hopefully peaked. For Bure, it is important to continue to work closely with its portfolio companies and develop their fine businesses. We will help them navigate challenging market conditions and maintain a long-term focus on competitive products and services as well as excellent customer relationships.
Bure's net asset value and holdings
| 2021/12/31 | 2022/12/31 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| SEK M | % of capital |
Net asset value |
Value change. |
(+/-) 1) Investment | Disposal | Net asset value |
% of net asset value |
Net asset value per share, SEK |
|
| ACQ Bure 3) | 20.0% | 761 | -43 | – | – | 718 | 4.9% | 9.7 | |
| Cavotec | 35.4% | 681 | -220 | – | -11 | 450 | 3.1% | 6.1 | |
| Mentice 4) | 14.7% | 359 | -226 | 9 | – | 142 | 1.0% | 1.9 | |
| L2) I |
Mycronic | 26.9% | 5,553 | -400 | – | – | 5,153 | 35.4% | 69.5 |
| S T |
Ovzon | 11.4% | 368 | -30 | – | – | 338 | 2.3% | 4.6 |
| E D |
Vitrolife | 15.9% | 12,046 | -8,041 | – | – | 4,005 | 27.5% | 54.0 |
| Xvivo Perfusion | 14.6% | 1,216 | -417 | – | – | 799 | 5.5% | 10.8 | |
| Total listed holdings | 20,985 | -9,378 | 9 | -11 | 11,605 | 79.7% | 156.5 | ||
| U | Allgon 5) | 92.4% | 746 | 11 | – | -4 | 753 | 5.2% | 10.2 |
| N | Atle Investment Management6) | 93.0% | 186 | 6 | 74 | -10 | 256 | 1.8% | 3.5 |
| L I |
Bure Growth 7) | 100.0% | 1,302 | 46 | 14 | – | 1,362 | 9.4% | 18.4 |
| S T |
Investment AB Bure 8) | – | 176 | 14 | – | -190 | – | – | – |
| E D |
Mercuri International 9) | 90.4% | 130 | -63 | 1 | – | 68 | 0.5% | 0.9 |
| Total unlisted holdings | 2,540 | 13 | 90 | -204 | 2,438 | 16.7% | 32.9 | ||
| Total holdings | 23,525 | -9,364 | 98 | -216 | 14,044 | 96.5% | 189.4 | ||
| T R E A S |
Cash and cash equivalents, short-term investments and other assets10) |
439 | 76 | 515 | 3.5% | 6.9 | |||
| U R |
Total treasury | 439 | 76 | 515 | 3.5% | 6.9 | |||
| Y | |||||||||
| Total net asset value | 23,964 | -9,364 | 175 | -216 | 14,559 | 100.0% | 196.3 |
1) Change in value including exit gains/losses.
2) Bure's number of shares at 31 December 2022: ACQ Bure 7,000,000, Cavotec 33,321,619, Mentice 3,761,659, Mycronic 26,317,163,
Ovzon 5,861,034, Vitrolife 21,510,257 and Xvivo Perfusion 4,367,504. Bure has also 4,200,000 warrants in ACQ Bure.
3) Refers to stocks and warrants in ACQ Bure.
4) Bure subscribed for 117,600 shares in Mentice's rights issue for SEK 9M.
5) Bure divested 5.25 million shares in Allgon to AMIP AB – a company owned by Bure and the management and board of Allgon. Bure's direct and indirect holdings in Allgon amount to 92.4 per cent.
6) Atle acquired shares in HealthInvest Partner, paid additional purchase costs for Atle Investment Services and Humle Fonder and submitted a conditional shareholder contribution to Atle Investment Management for a total of SEK 61M. Atle divested shares in Alcur Fonder, HealthInvest Partners and TIN Fonder to employees of the company for SEK 10M. The holdings in Alcur Fonder, Atle Investment Services and Fondbolaget Fondita were revalued by SEK 13M. Atle acquired units in the HealthInvest Sustainable Healthcare fund for SEK 10M.
7) Bure Growth acquired shares for SEK 13M in My Driving Academy's rights issue. The holding in My Driving Academy was revalued by SEK 5M due to the acquisition. Bure Growth acquired shares in ScandiNova Systems for SEK 2M. The holding in ScandiNova Systems was revalued by SEK 40M. 8) Investment AB Bure divested to Sandahlsbolagen Sweden.
9) Fair value of equity and interest-bearing receivables. The holding in Mercuri was devalued by SEK 63M.
10) Cash and cash equivalents, participations in funds and short-term investments in market-listed assets, other unlisted companies, interest-bearing receivables and other net assets.

Change in net asset value during 2022
Listed portfolio companies
Listed portfolio companies accounted for 79.7 per cent of net asset value compared to 87.6 per cent at the end of 2021. The total value of listed portfolio companies decreased SEK 9,380M to SEK 11,605M.
Value changes
Value changes due to fluctuations in share prices and exits during the period was SEK -9 378M.
Value changes in SEK M and share price performance 2022
| Ovzon | -30 | -8.3% |
|---|---|---|
| ACQ Bure (shares + warrants) | -43 | -6.3% |
| Cavotec | -220 | -32.5% |
| Mentice | -226 | -61.7% |
| Mycronic | -400 | -7.2% |
| Xvivo Perfusion | -417 | -34.3% |
| Vitrolife | -8,041 | -66.8% |
| Total | -9,378 |
Bure's comparative index, the SIX RX, fell 22.8 per cent.
Acquisitions
Bure acquired 117,600 shares in Mentice's rights issue for SEK 9M.
Divestments
Bure divested 750,000 shares in Cavotec to David Pagels, Cavotec CEO, for SEK 11M.
Dividends received
Bure received dividends of SEK 96M from listed portfolio companies.
Unlisted portfolio companies
Unlisted portfolio companies accounted for 16.7 per cent of net asset value compared to 10.6 per cent at the end of 2021.
The value of unlisted portfolio companies decreased SEK 102M to SEK 2,438M.
Acquisitions and value changes
Atle acquired shares in HealthInvest Partners, paid additional purchase costs for Atle Investment Services and Humle Fonder, and submitted a conditional shareholder contribution to Atle Investment Services for a total of SEK 61M. The holdings in Alcur Fonder, Atle Investment Services and Fondbolaget Fondita were revalued by SEK 13M. Atle acquired units in the HealthInvest Sustainable Healthcare fund for SEK 10M.
My Driving Academy acquired Mårtenssons, creating Sweden's largest driving school. Bure Growth acquired shares for SEK 13M in My Driving Academy's rights issue. The holding in My Driving Academy was revalued by SEK 5M due to the transaction.
Bure Growth acquired shares in ScandiNova Systems for SEK 2M. The holding in ScandiNova Systems was revalued by SEK 40M to due to the transaction.
The holding in Mercuri was devalued by SEK 63M.
Divestments
Bure divested Investment AB Bure to Sandahlsbolagen Sweden.
Atle divested shares in Alcur Fonder, HealthInvest Partners and TIN Fonder to employees of the company for SEK 10M.
Dividends received
Atle Investment Management received dividends of SEK 120M from the co-owned asset management companies.
Treasury
The value of assets in Treasury increased SEK 76M to SEK 515M. During the year, Bure acquired financial assets for SEK 98M and divested financial assets for SEK 216M. The group received dividends of SEK 217M and paid dividends of SEK 167M. Other changes amounting
to SEK -92M were due to changes in working capital, value changes in short-term investments and administrative costs.
Assets in Treasury amounted to 3.5 per cent of net asset value compared to 1.8 per cent at the end of 2021.
The Bure share
The total number of Bure shares amounts to 74,252,057, of which 74,146,921 are outstanding. The Bure Annual General Meeting (AGM) of 3 May 2022 authorised the Bure Board of Directors to decide on the buyback of up to 10 per cent of the total number of ordinary shares in Bure Equity AB. Bure did not repurchase any ordinary shares in 2022, nor does it hold any own ordinary shares.
With the backing of an authorisation from the AGM of 3 May 2022, Bure carried out a rights issue and then immediately repurchased 105,136 class C shares. The shares were issued and repurchased in accordance with the LTIP 2022 incentive programme which was adopted by the AGM on 3 May 2022.
| 22 Feb 2023 |
31 Dec 2022 |
31 Dec 2021 |
31 Dec 2020 |
|
|---|---|---|---|---|
| Share price, SEK | 260.6 | 246.4 | 438.2 | 293.6 |
| Dividend per share, SEK | – | 2.25 | 2.0 | 1.0 |
| Total return since year-end 1) | 5.8% | -43.1% | 50.1% | 39.2% |
| Net asset value per share, SEK | 215.5 | 196.3 | 323.2 | 239.6 |
| Development of NAV per share | 9.7% | -39.2% | 34.9% | 21.8% |
| SIX Return Index | 8.8% | -22.8% | 39.3% | 14.8% |
1) Including dividends of SEK 2.25 per share for 2022, SEK 2.00 per share for 2021 and SEK 1.00 per share for 2020.
Development of Bure's net asset value and share price per share

| Portfolio companies Jan–Dec 2022 and 2021 Listed SEK M |
2022 | 2021 | |
|---|---|---|---|
| Net sales | 0 | 0 | |
| EBIT | -15 | -7 | |
| EBIT margin | n/m | n/m | |
| Holding | 20.0% | 20.0% | |
| Net sales | 1,572 | 1,175 | |
| EBIT | -48 | -8 | |
| EBIT margin | -3.0% | -0.6% | |
| Holding | 35.4% | 36.2% | |
| Net sales | 218 | 185 | |
| EBIT | -24 | -20 | |
| EBIT margin | -11.0% | -10.7% | |
| Holding | 14.7% | 14.7% | |
| Net sales | 5,119 | 4,635 | |
| EBIT | 894 | 1,049 | |
| EBIT margin | 17.5% | 22.6% | |
| Holding | 26.9% | 26.9% | |
| Net sales | 357 | 191 | |
| EBIT | -47 | -113 | |
| EBIT margin | -13.2% | -59.2% | |
| Holding | 11.4% | 11.4% | |
| Net sales | 3,234 | 1,681 | |
| EBIT | 654 | 435 | |
| EBIT margin | 20.2% | 25.9% | |
| Holding | 15.9% | 15.9% | |
| Net sales | 415 | 258 | |
| EBIT | 6 | -18 | |
| EBIT margin | 1.5% | -7.2% | |
| Holding | 14.6% | 14.8% | |
| Unlisted SEK M | |||
| Net sales | 617 | 527 | |
| EBIT | 96 | 60 | |
| EBIT margin | 15.5% | 11.4% | |
| Holding | 92.4% | 100.0% | |
| Net sales | 0 | 0 | |
| EBIT | 123 | 151 | |
| EBIT margin | n/m | n/m | |
| Holding | 93.0% | 93.0% | |
| Net sales | 0 | 0 | |
| EBIT | 46 | 32 | |
| EBIT margin | n/m | n/m | |
| Holding | 100.0% | 100.0% | |
| Net sales | 325 | 303 | |
| EBIT | 2 | 7 | |
| EBIT margin | 0.5% | 2.3% | |
| Holding | 90.4% | 90.4% |
Listed portfolio companies

Share of Bure's net asset value: 4.9%
ACQ Bure is a Swedish acquisition company. ACQ's investment strategy is to identify and conduct the acquisition of a company that can create value for shareholders over time.
| Key figure SEK m |
Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 0 | 0 | 0 | 0 | 0 |
| Operating expenses | -5 | -3 | -15 | -7 | -2 |
| EBIT | -5 | -3 | -15 | -7 | -2 |
| EBIT margin | n/m | n/m | n/m | n/m | n/m |
| Net financial items | 11 | 0 | 15 | 0 | 0 |
| Profit/loss before tax | 6 | -3 | -1 | -7 | -2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Profit/loss for the period | 6 | -3 | -1 | -7 | -2 |
| Net loan debt (-)/ receivable (+) |
3,426 | 3,441 | 20 | ||
| Total assets | 3,441 | 3,442 | 20 | ||
| Equity | 3,439 | 3,440 | 18 | ||
| Cash flow from operating activities |
-16 | -7 | 0 | ||
| Average no. of employees | 0 | 0 | 0 |
| Facts at 31 December 2022 | Largest shareholders | |
|---|---|---|
| NAV: SEK 718M1) | Bure Equity | 20.0% |
| Acquisition date: 2021 | AMF Pension & Fonder | 20.0% |
| Board member from Bure: | SEB Fonder & Stiftelse | 11.7% |
| Patrik Tigerschiöld, chairman | Others | 48.3% |
| Sarah McPhee, board member | ||
| 1) Relates to shares and warrants in ACQ Bure. |
The quarter in brief
• The share price increased 3.8 per cent in the fourth quarter 2022.

www.cavotec.com
Share of Bure's net asset value: 3.1%
Cavotec is a leading engineering group that designs and manufactures automated connection and electrification systems for ports and industrial applications worldwide.
| Key figure EUR m |
Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 47 | 31 | 148 | 116 | 158 |
| Operating expenses | -48 | -33 | -152 | -117 | -155 |
| EBIT | -2 | -2 | -5 | -1 | 4 |
| EBIT margin | -3.5% | -5.4% | -3.0% | -0.6% | 2.2% |
| Net financial items | -4 | 1 | -1 | 3 | -7 |
| Profit/loss before tax | -5 | -1 | 0 | 3 | -3 |
| Income tax expense | -1 | -3 | -3 | -4 | -1 |
| Profit/loss for the period continuing operations |
-7 | -4 | -3 | -1 | -4 |
| Profit/loss for the period discontinued operations |
-1 | -33 | -11 | -36 | – |
| Profit/loss for the period | -8 | -36 | -14 | -37 | -4 |
| Net loan debt (-)/ receivable (+) |
-30 | -15 | -14 | ||
| Total assets | 168 | 175 | 201 | ||
| Equity | 44 | 67 | 106 | ||
| Cash flow from operating activities |
-21 | 1 | 16 | ||
| Average no. of employees | 640 | 815 | 747 |
| Facts at 31 December 2022 | Largest shareholders | |
|---|---|---|
| NAV: SEK 450M | Bure Equity | 35.4% |
| Acquisition date: 2014 | Thomas von Koch | 11.9% |
| Board member from Bure: | Others | 52.7% |
| Patrik Tigerschiöld, chairman |
- Net sales increased 49 per cent to EUR 47M (31).
- Operating profit was EUR -2M (-2).
- Cavotec received an order for mobile shore power worth EUR 6M from the Port of Miami.
- The share price fell 9.1 per cent in the fourth quarter 2022.

www.mentice.com
Share of Bure's net asset value: 1.0%
Mentice develops and sells turn-key simulation solutions targeting the fast-growing market for endovascular procedures.
| Key figure SEK m |
Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 69 | 68 | 218 | 185 | 138 |
| Operating expenses | -62 | -64 | -242 | -205 | -156 |
| EBIT | 7 | 4 | -24 | -20 | -18 |
| EBIT margin | 9.6% | 5.9% -11.0% -10.7% -13.2% | |||
| Net financial items | 0 | 0 | 0 | -2 | 0 |
| Profit/loss before tax | 7 | 3 | -24 | -21 | -19 |
| Income tax expense | -5 | -7 | -7 | -8 | 5 |
| Profit/loss for the period | 2 | -4 | -31 | -29 | -13 |
| Net loan debt (-)/ receivable (+) |
31 | -2 | 37 | ||
| Total assets | 333 | 262 | 245 | ||
| Equity | 163 | 137 | 163 | ||
| Cash flow from operating activities |
15 | -5 | 31 | ||
| Average no. of employees | 122 | 104 | 95 |
| Facts at 31 December 2022 | Largest shareholders | ||
|---|---|---|---|
| NAV: SEK 142M | Karin Howell-Bidermann | 34.0% | |
| Acquisition date: 2019 | Bure Equity | 14.7% | |
| Board member from Bure: | Handelsbanken Fonder | 7.5% | |
| Gösta Johannesson, board member | Others | 43.8% |
The quarter in brief
- Orders amounted to SEK 90M (74). The order book at year-end was SEK 126M (87).
- Net sales increased 1 per cent to SEK 69M (68).
- Operating profit was SEK 7M (4).
- Mentice acquired all assets for the software solution Ankyras from the Spanish the company Galgo Medical S.L. for SEK 19 million. Mentice carried out a new issue of SEK 60 million. Bure subscribed to its pro rata share of the issue of SEK 9 million.
- The share price fell 11.1 per cent in the fourth quarter 2022.
www.mycronic.com
Share of Bure's net asset value: 35.4%
Mycronic creates world-leading production equipment for electronics and display manufacturing.
| Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|
| 1,497 | 1,295 | 5,119 | 4,635 | 3,882 |
| -3,586 -2,984 | ||||
| 262 | 204 | 894 | 1,049 | 898 |
| 22.6% 23.1% | ||||
| 1 | -1 | -4 | -2 | -8 |
| 263 | 203 | 890 | 1,046 | 890 |
| -154 | -219 | -187 | ||
| -16 | -26 | |||
| 247 | 177 | 737 | 827 | 703 |
| 1,004 | 440 | 1,039 | ||
| 7,340 | 6,136 | 5,319 | ||
| 4,703 | 3,997 | 3,378 | ||
| 853 | 998 | 1,126 | ||
| -1,235 -1,091 -4,225 17.5% 15.8% 17.5% |
| Facts at 31 December 2022 | Largest shareholders | |
|---|---|---|
| NAV: SEK 5,153M | Bure Equity | 26.9% |
| Acquisition date: 2010 via | SEB Fonder | 10.3% |
| Skanditek | Fjärde AP-fonden | 9.1% |
| Board member from Bure: Patrik Tigerschiöld, chairman |
Others | 53.7% |
- Orders amounted to SEK 2,529M (1,234), an increase of 105 per cent. The combined order book at the end of the year was SEK 3,574M (1,975).
- Net sales increased 16 per cent to SEK 1,497M (1,295).
- Operating profit amounted to SEK 262M (204), equivalent to an operating margin of 17.5 per cent (15.8).
- The share price increased 45.0 per cent in the fourth quarter 2022.
www.ovzon.com
Share of Bure's net asset value: 2.3%
Mentice develops and sells turn-key simulation solutions targeting the fast-growing market for endovascular procedures.
| Key figure SEK m |
Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 101 | 73 | 357 | 191 | 160 |
| Operating expenses | -110 | -102 | -404 | -305 | -209 |
| EBIT | -9 | -29 | -47 | -113 | -48 |
| EBIT margin | -8.6% -39.7% -13.2% -59.2% -30.1% | ||||
| Net financial items | 0 | 7 | 45 | 29 | -59 |
| Profit/loss before tax | -9 | -22 | -2 | -84 | -107 |
| Income tax expense | 0 | 0 | 0 | 0 | 3 |
| Profit/loss for the period | -9 | -22 | -2 | -84 | -104 |
| Net loan debt (-)/ receivable (+) |
-202 | 82 | 180 | ||
| Total assets | 1 956 | 1,853 | 1,329 | ||
| Equity | 1 427 | 1,450 | 1,293 | ||
| Cash flow from operating activities |
-116 | -77 | -155 | ||
| Average no. of employees | 43 | 36 | 31 |
| Facts at 31 December 2022 | Largest shareholders | ||
|---|---|---|---|
| NAV: SEK 338M | Investment AB Öresund | 11.9% | |
| Acquisition date: 2018 | Bure Equity | 11.4% | |
| Board member from Bure: | Futur Pension | 9.6% | |
| Patrik Tigerschiöld, board member | Others | 67.1% |
The quarter in brief
- Net sales increased 38 per cent to SEK 101M (73).
- Operating profit was SEK -9M (-29).
- The share price increased 53.8 per cent in the fourth quarter 2022.
- After the balance sheet date, Ovzon informed about the postponement of the launch of Ovzon 3 and change to SpaceX as launch partner.
- Ovzon carried out a directed share issue of SEK 200M. Bure subscribed for 1,123,595 shares for SEK 50M. The issue will be registered after a decision at an extraordinary general meeting in Ovzon on March 3, 2023.
www.vitrolife.com
Share of Bure's net asset value:27.5%
Vitrolife is an international medtech group. It develops, produces and markets fertility treatment products.
| Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|
| 855 | 514 | 3,234 | 1,681 | 1,246 |
| -687 | -1,245 | -876 | ||
| 168 | 40 | 654 | 435 | 370 |
| 19.6% | 25.9% 29.7% | |||
| -63 | 22 | -117 | 25 | -4 |
| 106 | 61 | 537 | 460 | 366 |
| -32 | -28 | -143 | -116 | -78 |
| 73 | 34 | 394 | 344 | 288 |
| -1,563 | -1,852 | 911 | ||
| 20,551 19,429 | 2,305 | |||
| 16,740 15,341 | 2,017 | |||
| 636 | 384 | 356 | ||
| -475 -2,580 7.7% 20.2% |
| Facts at 31 December 2022 | Largest shareholders | |||
|---|---|---|---|---|
| NAV: SEK 4,005M | William Demant Invest A/S | 28.7% |
| Acquisition date: 2010 | Bure Equity | 15.9% |
|---|---|---|
| via Skanditek | EQT | 4.5% |
| Board member from Bure: | Others | 50.9% |
| Henrik Blomquist, board member |
- Net sales increased 66 per cent to SEK 855M (514), of which currency effects amounted to 18 per cent, acquired growth 37 per cent, and organic growth 11 per cent.
- Operating profit before depreciation (EBITDA) amounted to SEK 273M (85), equivalent to a margin of 31.9 per cent (16.5).
- The share price increased 17.1 per cent in the fourth quarter 2022.
- After the balance sheet date, Bronwyn Brophy was appointed CEO of Vitrolife with effect from 1 August 2023.
www.xvivoperfusion.com
Share of Bure's net asset value:5.5%
Xvivo Perfusion is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives.
| Key figure SEK m |
Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 132 | 86 | 415 | 258 | 180 |
| Operating expenses | -129 | -94 | -409 | -277 | -226 |
| EBIT | 2 | -8 | 6 | -18 | -46 |
| EBIT margin | 1.8% | -9.7% | 1.5% | -7.2% -25.4% | |
| Net financial items | 0 | 19 | 16 | 25 | -12 |
| Profit/loss before tax | 3 | 10 | 22 | 7 | -57 |
| Income tax expense | -2 | 2 | -4 | 1 | 14 |
| Profit/loss for the period | 1 | 12 | 18 | 8 | -44 |
| Net loan debt (-)/ receivable (+) |
237 | 393 | 347 | ||
| Total assets | 1,733 | 1,543 | 1,150 | ||
| Equity | 1,430 | 1,285 | 1,008 | ||
| Cash flow from operating activities |
28 | -12 | -12 | ||
| Facts at 31 December 2022 | Largest shareholders | |
|---|---|---|
| NAV: SEK 799M | Bure Equity | 14.6% |
| Acquisition date: Lex Asea | Swedbank Robur Fonder | 9.7% |
| distribution from Vitrolife in 2012 | Fjärde AP-fonden | 9.2% |
| Board member from Bure: | Others | 66.5% |
| Gösta Johannesson, chairman |
- Net sales amounted to SEK 132M, equivalent to growth of 53 per cent in SEK and 34 per cent excluding currency effects. Organic growth accounted for 27 per cent and acquired growth 7 per cent.
- All business areas reported underlying growth adjusted for currency effects: Thorax 26 per cent, Abdominal 27 per cent, and Services 44 per cent.
- Operating profit before depreciation (EBITDA) amounted to SEK 14M (0), equivalent to a margin of 10 per cent (0).
- Xvivo completed the acquisition of machine and perfusion operations from Italian distributor Avionord S.r.l. A directed rights issue was conducted to Avionord S.r.l. shareholders, which increased the number of shares and votes in Xvivo by 269,952.
- Christoffer Rosenblad was appointed CEO of Xvivo.
- The share price increased 36.6 per cent in the fourth quarter 2022.
Unlisted portfolio companies
www.allgon.se
Share of Bure's net asset value: 5.2%
Allgon is a world-leading actor in industrial radio remote controls. The company develops, manufactures, and delivers industrial radio remote control solutions for customers worldwide.
| Key figure SEK m |
Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 159 | 134 | 617 | 527 | 443 |
| Operating expenses | -129 | -129 | -521 | -467 | -412 |
| EBIT | 29 | 5 | 96 | 60 | 31 |
| EBIT margin | 18.5% | 3.7% 15.5% | 11.4% | 7.1% | |
| Net financial items | -1 | -1 | -6 | -21 | -24 |
| Profit/loss before tax | 28 | 4 | 89 | 39 | 8 |
| Income tax expense | -7 | 5 | -17 | -4 | -17 |
| Results from ongoing operations |
21 | 9 | 73 | 35 | -9 |
| Results from discontinued operations |
0 | 0 | 0 | 40 | -24 |
| Profit/loss for the period | 21 | 9 | 73 | 75 | -33 |
| Net loan debt (-)/ receivable (+) |
-172 | -210 | -237 | ||
| Total assets | 830 | 737 | 689 | ||
| Equity | 460 | 365 | 281 | ||
| Cash flow from operating activities |
60 | 40 | 36 | ||
| Average no. of employees | 377 | 360 | 345 |
| Facts at 31 December 2022 | Largest shareholders | |
|---|---|---|
| NAV: SEK 753M | Bure Equity | 92.4% |
| Acquisition date: 2021 | Management and board | |
| Board member from Bure: | of Allgon | 7.6% |
| Sophie Hagströmer, chairman | ||
| Trolle Sahlström, board member |
The quarter in brief
- Net sales increased 18 per cent to SEK 159M (134).
- Operating profit was SEK 29M (5), equivalent to a margin of 18.5 per cent (3.7).
- Net debt decreased to SEK 172M (210).
www.atle.se
Share of Bure's net asset value: 1.8%
Atle Investment Management invests in financial services and assets. The company owns 30.4 per cent of Alcur Fonder, 100 per cent of Atle Investment Services, 20.1 per cent of Fondbolaget Fondita, 45,8 per cent of HealthInvest Partners, 100 per cent of Humle Fonder, 35.2 per cent of Teknik Innovation Norden Fonder (TIN Fonder) and holdings in equity funds.
| Key figure SEK m |
Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 0 | 0 | 0 | 0 | 0 |
| Dividends | 0 | 0 | 120 | 98 | 21 |
| Fair value of financial assets |
-4 | 1 | 11 | 58 | 4 |
| Management costs | -2 | -2 | -8 | -5 | -5 |
| EBIT | -7 | 0 | 123 | 151 | 20 |
| Net financial items | -1 | 0 | -3 | -1 | 0 |
| Profit/loss before tax | -8 | -1 | 120 | 150 | 20 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Profit/loss for the period | -8 | -1 | 120 | 150 | 20 |
| Net loan debt (-)/ receivable (+)2) |
-73 | -12 | -20 | ||
| Total assets | 284 | 229 | 120 | ||
| Equity | 191 | 187 | 96 | ||
| Cash flow from operating activities |
109 | 95 | 16 | ||
| Average no. of employees | 1 | 1 | 1 |
1) Of which, SEK 81M is liable to the Parent Company as at 31 December 2022.
| Facts at 31 December 2022 | Largest shareholders | |||
|---|---|---|---|---|
| NAV: SEK 256M | Bure Equity | 93.0% |
| Acquisition date: Established 2014 | Gustav Ohlsson | 7.0% |
|---|---|---|
| Board member from Bure: | ||
Henrik Blomquist, chairman, Oskar Hörnell, board member, Sarah McPhee, board member
- Assets under managemernt in Alcur Fonder, Atle Investment Services, Fondita, HealthInvest Partners, Humle Fonder and TIN Fonder decreased to SEK 33 billion compared to SEK 44 billion at the beginning of the year.
- Atle received additional purchase payments for Humle Fonder and acquired shares in the HealthInvest Sustainable Healthcare fund for a total of SEK 17 M.
- Atle divested 5.2 per cent of shares in HealthInvest Partners to employees of the company.
- Atle revalued the holdings in Atle Investment Services and Fondbolaget Fondita by SEK -5M.

www.bure.se
Share of Bure's net asset value: 9.4%
Bure Growth is a wholly owned company that invests in development companies. The company owns 46.5 per cent of BioLamina, 30.4 per cent of My Driving Academy Sweden, 27.9 per cent of ScandiNova Systems and 17.6 per cent of Yubico.
| Key figure SEK m |
Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 0 | 0 | 0 | 0 | 0 |
| Fair value of financial assets |
0 | 0 | 46 | 32 | 56 |
| Administrative expense | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | 0 | 46 | 32 | 56 |
| Net financial items | 0 | 0 | 0 | 0 | 0 |
| Profit/loss before tax | 0 | 0 | 46 | 32 | 56 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Profit/loss for the period | 0 | 0 | 46 | 32 | 56 |
| Net loan debt (-)/ receivable (+) 1) |
-449 | -435 | -429 | ||
| Total assets | 1,362 | 1,303 | 1,265 | ||
| Equity | 894 | 848 | 817 | ||
| Cash flow from operating activities |
0 | 0 | 0 | ||
| Average no. of employees | 0 | 0 | 0 |
1) Of which, SEK 449M is liable to the Parent Company as at 31 December 2022.
| Facts at 31 December 2022 | Largest shareholders | |
|---|---|---|
| NAV: SEK 1,362M | Bure Equity | 100.0% |
| Acquisition date: Established 2015 | ||
| Board member from Bure: | ||
| Henrik Blomquist, chairman | ||
| Sophie Hagströmer, board member | ||
| Max Jonson, board member |

www.mercuri.se
Share of Bure's net asset value: 0.5%
Mercuri International is a leading sales and management training consultancy and is present worldwide
| Key figure SEK m |
Q4 2022 |
Q4 2021 |
2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 101 | 90 | 325 | 303 | 241 |
| Operating expenses | -91 | -86 | -323 | -299 | -271 |
| EBITA | 9 | 5 | 2 | 4 | -30 |
| EBITA margin | 9.1% | 5.1% | 0.5% | 1.4% -12.3% | |
| Impairments of intangible fixed assets |
– | – | – | – | -15 |
| EBIT | 9 | 5 | 2 | 4 | -45 |
| EBIT margin | 9.1% | 5.1% | 0.5% | 1.4% -18.7% | |
| Net financial items | -3 | -2 | -1 | -4 | -6 |
| Profit/loss before tax | 6 | 3 | 1 | 0 | -51 |
| Income tax expense | -5 | -1 | -6 | -4 | -1 |
| Profit/loss for the period | 2 | 2 | -5 | -4 | -52 |
| Net loan debt (-)/ receivable (+) |
-92 | -79 | -103 | ||
| Total assets | 346 | 320 | 305 | ||
| Equity | 118 | 105 | 100 | ||
| Cash flow from operating activities |
-8 | 31 | -5 | ||
| Average no. of employees | 194 | 202 | 216 |
1) Of which, SEK 33M is liable to the Parent Company as at 31 December 2022.
| Facts at 31 December 2022 | Largest shareholders | ||
|---|---|---|---|
| NAV: SEK 68M1) | Bure Equity | 90.4% | |
| Acquisition date: 1998 | Others | 9.6% | |
| Board member from Bure: | |||
Henrik Blomquist, chairman
1) Fair value of equity and interest-bearing receivables.
- Sales increased 12 per cent to SEK 101M (90).
- EBIT was SEK 9M (5), and EBIT margin was 9.1 per cent (5.1).
- Bure's holding of shares in Mercuri was devalued by SEK 63M.
Bure Year-end Report 2022
Bure is an investment entity, which means that the holdings varies in line with its acquisitions and divestitures. Since this makes the Group's consolidated statements difficult to analyse, the development and financial position of the companies should also be analysed on an individual basis. More detailed information on portfolio companies are presented on pages 6–11.
Consolidation principles from 1January 2021
Bure Equity is an investment entity in accordance with IFRS 10 - Investment entity.
An investment company does not consolidate subsidiaries in accordance with IFRS 10 Consolidated Financial Statements and does not apply IFRS 3 Business Combinations, with the exception of subsidiaries that are active in investment activities. An investment entity values portfolio companies at fair value in accordance with IFRS 9 Financial Instruments.
Since 1 January 2021, the Bure Group consists of the parent company Bure Equity AB, Atle Investment Management AB, and Bure Growth AB. For more information, please see Note 1 – Accounting principles.
GROUP Results for the fourth quarter of 2022
Group earnings from investment activities amounted to SEK 2,421M (1,304).
Dividends amounted to SEK 0M (0).
Fair value changes from financial assets amounted to SEK 2,420M (1,302).
Operating profit for the period was SEK 2,405M (1,281). Net financial items amounted to SEK 4M (1). Profit after financial items was SEK 2,409M (1,282).
Profit after tax was SEK 2,409M (1,282). Other comprehensive income included translation differences of SEK 0M (0).
Results for January – December 2022
Group earnings from investment activities amounted to SEK -9,166M (6,437). Dividends amounted to SEK 217M (197). Fair value changes from financial assets amounted to SEK -9,390M (6,235).
Operating profit for the period was SEK -9,246M (6,358). Net financial items amounted to SEK 12M (4). Profit after financial items was SEK -9,235M (6,362). Profit after tax was SEK -9,235M (6,362).
Other comprehensive income included translation differences of 0M (0).
Financial position
Group equity at the end of the year amounted to SEK 14,548M (23,956) and the equity to assets ratio was 99 per cent (100). At the end of the year , the group had reported net receivables of SEK 456M (469), which consisted of interest-bearing assets of SEK 549M (474) and interest-bearing liabilities of SEK 3M (4). Group equity per share amounted to SEK 195,9 compared to SEK 323.1 per share on December 31, 2021.
PARENT COMPANY Results for the fourth quarter of 2022
Earnings from investment activities was SEK 2,426M (1,303). Dividends amounted to SEK 0M (0). Fair value changes from financial assets amounted
to SEK 2,424M (1,300). Administrative costs amounted to SEK 14M (20). Net financial items amounted to SEK 5M (1). Profit after tax was SEK 2,417M (1,284).
Results for January – December 2022
Earnings from investment activities was SEK -9,237M (6,304). Dividends amounted to SEK 202M (153). Fair value changes from financial assets amounted to SEK -9,446M (6,146). Administrative costs amounted to SEK 72M (72). Net financial items amounted to SEK 15M (5). Profit after tax was SEK -9,294M (6,237).
Financial position
Equity in the Parent Company at the end of the year amounted to SEK 13,484 M (22,944) and the equity to assets ratio was 100 per cent (100). At the end of the period, the Parent Company had a reported net receivables of SEK 520M (480), which consisted of interest-bearing assets of 523M (484) and interest-bearing liabilities of SEK 3M (4). Receivables from Atle Investment Management and Bure Growth amounted to SEK 531M (477).
Group acquisitions and disposals
Bure acquired 117,600 shares in Mentice's rights issue for SEK 9M.
Atle acquired shares in HealthInvest Partners, paid additional purchase costs for Atle Investment Services and Humle Fonder, and submitted a conditional shareholder contribution to Atle Investment Services for a total of SEK 61M.
My Driving Academy acquired Mårtenssons and created Sweden's largest driving school. Bure Growth acquired shares for SEK 13M in My Driving Academy's rights issue. Bure Growth acquired shares in ScandiNova Systems for SEK 2M.
Bure divested Investment AB Bure to Sandahlsbolagen Sweden.
Bure divested 750,000 shares in Cavotec to David Pagels, Cavotec CEO, for SEK 11M.
Group loss carryforward
Group loss carryforward at the end of 31 December 2022 amounted to SEK 782M, of which SEK 756M pertained to the Parent Company. Losses attributable to Sweden amounted to SEK 782M and are perpetual. The deferred tax asset based on loss carryforwards in the Group has been valued at SEK 0M (0).
Currency exposure
The majority of consolidated revenue is denominated in SEK and EUR. Underlying costs are generally incurred in the same currency as revenues, thereby limiting transaction exposure.
Related party transactions
ACQ Bure AB (publ.) is a Swedish acquisition company listed on the Nasdaq Stockholm. Bure's holding in ACQ Bure amounts to 20 per cent. Since 21 December 2020, Henrik Blomquist, (CEO of Bure Equity), has served as CEO of ACQ Bure on a consulting basis, Max Jonson, (CFO of Bure Equity), has served as CFO on a consulting basis and Oskar Hörnell (Investment Manager of Bure Equity) has served as a consultant of ACQ Bure. Bure Equity also assists ACQ Bure with investment advisory services. Contracts are entered into on market terms. Bure Equity has invoiced ACQ Bure since the beginning of the second quarter of 2021. No other transactions with related parties have taken place during the period.
Ownership structure
Bure's largest shareholders on 31 December 2022 were Patrik Tigerschiöld including related parties with 10.4 per cent, AMF Tjänstepension & Fonder 9.5 per cent, the Björkman family including foundations with 8.2 per cent, Fjärde AP-fonden 7.8 per cent and SEB Investment Management 6.8 per cent. According to Euroclear, the number of shareholders on 31 December 2022 was 58,680.
Events after the balance sheet date
The board proposes to the annual general meeting an ordinary dividend of SEK 2.25 per share (2.25).
Bure subscribed for 1,123,595 shares in Ovzon's rights issue for SEK 50M. The issue is planned to be conducted following a decision at an extraordinary general meeting of Ovzon on the 3 March 2023.
Significant risks and uncertainties
In view of the rapid on the financial markets, special emphasis is placed on monitoring the effects of Bure's investments and their valuations. Bure has a number of basic principles regarding the management of risk. Bure's financial policy states that the Parent Company shall be essentially debt-free. Furthermore, each portfolio company shall be financially independent from the Parent Company, which means that the Parent Company is not financially liable for portfolio companies' obligations, and that portfolio companies are responsible for their own financing.
Financing of respective portfolio companies shall be appropriate to each company's specific circumstances, such that overall risk is managed through a balance between operational and financial risk.
Bure's 2021 annual report provides a detailed description of the Group's risk exposure and risk management in the administration report and in Note 19. Bure's assessment is that no significant risks have arisen other than those described in the annual report and in this interim report. This interim report has not been subject to review by the auditors.
Stockholm 23 February 2023
Bure Equity AB (publ)
Patrik Tigerschiöld (Chairman)
Carl Björkman Carsten Browall
Charlotta Falvin Sarah McPhee Birgitta Stymne Göransson
Henrik Blomquist (CEO)
Statement of comprehensive income
| SEK M | Q4 2022 |
Q4 2021 |
Full year 2022 |
Full year 2021 |
|---|---|---|---|---|
| Operating income | ||||
| Net sales | 0 | 0 | 0 | 0 |
| Dividends | – | – | 217 | 197 |
| Fair value financial assets | 2,420 | 1,302 | -9,390 | 6,235 |
| Other operating income | 2 | 2 | 7 | 5 |
| Total operating income | 2,421 | 1,304 | -9,166 | 6,437 |
| Operating expenses | ||||
| Other external expenses | -6 | -6 | -26 | -24 |
| Personnel costs | -9 | -16 | -49 | -51 |
| Amortization and write-downs of intangible and tangible fixed assets | -1 | -2 | -4 | -4 |
| Total operating expenses | -16 | -23 | -80 | -79 |
| Operating profit/loss | 2,405 | 1,281 | -9,246 | 6,358 |
| Interest income and similar profit/loss items | 4 | 1 | 12 | 4 |
| Interest expenses and similar profit/loss items | 0 | 0 | 0 | -1 |
| Profit/loss after financial items | 2,409 | 1,282 | -9,235 | 6,362 |
| Tax on income for the period | 0 | 0 | 0 | 0 |
| Income for the period | 2,409 | 1,282 | -9,235 | 6,362 |
| Other comprehensive income | ||||
| Items that can be subsequently re-entered onto the income statement | ||||
| Translation differences | 0 | 0 | 0 | 0 |
| Other comprehensive income for the period, after tax | 0 | 0 | 0 | 0 |
| Total income for the period | 2,409 | 1,282 | -9,235 | 6,362 |
| Profit/loss attributable to non-controlling interests | -1 | 0 | 8 | 10 |
| Profit/loss attributable to owners of | ||||
| the Parent Company | ,2,410 | 1,282 | -9,243 | 6,352 |
| Comprehensive income attributable to | ||||
| non-controlling interests | -1 | 0 | 8 | 10 |
| Comprehensive income attributable to | ||||
| non-controlling interests | 2,410 | 1,282 | -9,243 | 6,352 |
| Average number of outstanding shares before dilution, thousands1) | 74,147 | 74,147 | 74,147 | 74,147 |
| Average number of outstanding shares post dilution, thousands1) | 74,202 | 74,147 | 74,161 | 74,147 |
| Earnings per share attributable to the parent company's shareholders before dilution, SEK1) |
32.50 | 17.29 | -124.66 | 85.67 |
| Earnings per share attributable to the parent company's shareholders | ||||
| post dilution, SEK1) | 32.48 | 17.29 | -124.63 | 85.67 |
1) As of December 31, 2022, the number of possible additional ordinary shares amounts to 105,136. No dilutive effect as of December 31, 2021
Statement of financial position
| SEK M | 31 December 2022 |
31 December 2021 |
|---|---|---|
| Assets | ||
| Intangible and tangible fixed assets | 36 | 24 |
| Financial assets valued at fair value via the income statement | 14,027 | 23,366 |
| Long-term interest-bearing receivables | 41 | 145 |
| Long-term non-interest-bearing receivables | 1 | 1 |
| Financial assets | 14,069 | 23,512 |
| Total fixed assets | 14,105 | 23,536 |
| Short-term interest-bearing receivables | 2 | 3 |
| Other non-interest-bearing receivables | 4 | 6 |
| Financial investments | 116 | 133 |
| Cash and cash equivalents | 416 | 326 |
| Total current assets | 538 | 467 |
| Total assets | 14,643 | 24,004 |
| of which, interest-bearing assets | 459 | 474 |
| Equity and liabilities | ||
| Equity attributable to owners of the Parent Company | 14,535 | 23,943 |
| Equity attributable to non-controlling interests | 13 | 13 |
| Total equity | 14,548 | 23,956 |
| Provisions | 19 | 19 |
| Non-current liabilities | 53 | 3 |
| Current liabilities | 23 | 26 |
| Total liabilities | 95 | 47 |
| Total equity and liabilities | 14,643 | 24,004 |
| of which, interest-bearing liabilities | 3 | 4 |
Statement of changes in equity
| Share | Other contributed |
Retained, earnings incl. profit, for |
Non controlling |
Total | ||
|---|---|---|---|---|---|---|
| SEK M | capital | capital | Reserves | the year | interests | equity |
| Opening balance equity at 1 January 2021 | 576 | 1,660 | -60 | 15,507 | 20 | 17,702 |
| Adjustment transition to IFRS 10 investment entity | – | – | – | 58 | -14 | 44 |
| Adjusted opening balance as of January 1 2021 | 576 | 1,660 | -60 | 15,564 | 7 | 17,746 |
| Profit/loss for the year | – | – | – | 6,352 | 10 | 6,362 |
| Other comprehensive income | – | – | – | – | – | 0 |
| Cash dividend | – | – | – | -148 | – | -148 |
| Dividends paid to minority shareholders | – | – | – | – | -4 | -4 |
| Closing balance equity at 31 December 2021 | 576 | 1,660 | -60 | 21,768 | 13 | 23,956 |
| SEK M | Share capital |
Other contributed capital |
Reserves | Retained, earnings incl. profit, for the year |
Non controlling interests |
Total equity |
|---|---|---|---|---|---|---|
| Opening balance equity at 1 January 2022 | 576 | 1,660 | -60 | 21,768 | 13 | 23,956 |
| Profit/loss for the year | – | – | – | -9,243 | 8 | -9,235 |
| Other comprehensive income | – | – | – | – | – | 0 |
| Share-related remuneration LTIP 2022 | – | – | – | 1 | – | 1 |
| Issue of class C shares | 1 | – | – | – | – | 1 |
| Buyback of class C shares | – | – | – | -1 | – | -1 |
| Cash dividend | – | – | – | -167 | – | -167 |
| Dividends paid to minority shareholders | – | – | – | – | -8 | -8 |
| Closing balance equity at 31 December 2022 | 576 | 1,660 | -60 | 12,359 | 13 | 14,548 |
Statement of cash flows
| Q4 | Q4 | Full year | Full year | |
|---|---|---|---|---|
| SEK M | 2022 | 2021 | 2022 | 2021 |
| Cash flow from operating activities before changes | ||||
| in working capital | -7 | -17 | 177 | 971 |
| Cash flow from changes in working capital | 15 | 13 | 0 | 8 |
| Cash flow from operating activities | 7 | 5 | 176 | 980 |
| Cash flow from investing activities | -77 | -336 | 39 | -1,670 |
| Cash flow from financing activities | 51 | 0 | -125 | -151 |
| Cash flow for the period | -19 | -341 | 90 | -841 |
| Cash and cash equivalents at beginning of period | 435 | 667 | 326 | 1,167 |
| Cash flow for the period | -19 | -341 | 90 | -841 |
| Translation differences | 0 | 0 | 0 | 0 |
| Cash and cash equivalents at end of period | 416 | 326 | 416 | 326 |
Income statement
| Q4 | Q4 | Full year | Full year | |
|---|---|---|---|---|
| SEK M | 2022 | 2021 | 2022 | 2021 |
| Investment activities | ||||
| Dividends | 0 | 0 | 202 | 153 |
| Fair value financial assets | 2,424 | 1,300 | -9,446 | 6,146 |
| Other income | 2 | 2 | 7 | 5 |
| Total income | 2,426 | 1,303 | -9,237 | 6,304 |
| Personnel costs | -8 | -15 | -46 | -49 |
| Other external expenses | -5 | -5 | -24 | -21 |
| Depreciation of property, plant and equipment | -1 | -1 | -2 | -2 |
| Total management costs | -14 | -20 | -72 | -72 |
| Operating profit/loss | 2,412 | 1,283 | -9,309 | 6,232 |
| Financial income and expenses | ||||
| Interest income and similar profit/loss items | 5 | 1 | 15 | 6 |
| Interest expenses and similar profit/loss items | 0 | 0 | 0 | -1 |
| Total financial income and expenses | 5 | 1 | 15 | 5 |
| Financial income and expenses | 2,417 | 1,284 | -9,294 | 6,237 |
| Tax on income for the period | 0 | 0 | 0 | 0 |
| Profit/loss for the period1) | 2,417 | 1,284 | -9,294 | 6,237 |
| Average number of outstanding shares before dilution, thousands1) | 74,147 | 74,147 | 74,147 | 74,147 |
| Average number of outstanding shares post dilution, thousands1) | 74,202 | 74,147 | 74,161 | 74,147 |
| Earnings per share attributable to the parent company's shareholders before dilution, SEK1) |
32.60 | 17.31 | -125.35 | 84.12 |
| Earnings per share attributable to the parent company's shareholders post dilution, SEK1) |
32.58 | 17.31 | -125.33 | 84.12 |
| Average number of employees | 9 | 8 | 9 | 8 |
1) Corresponds to comprehensive income.
1) As of December 31, 2022, the number of possible additional ordinary shares amounts to 105,136. No dilutive effect as of December 31, 2021
Statement of financial position
| SEK M | 31 December 2022 |
31 December 2021 |
|---|---|---|
| Assets | ||
| Property, plant and equipment | 8 | 9 |
| Financial assets valued at fair value via the income statement | 12,394 | 21,893 |
| Shares in group companies | 21 | 21 |
| Long-term interest-bearing receivables | 33 | 145 |
| Long-term non-interest-bearing receivables | 1 | 1 |
| Financial assets | 12,448 | 22,060 |
| Total fixed assets | 12,456 | 22,069 |
| Short-term interest-bearing receivables | 83 | 44 |
| Other non-interest-bearing receivables | 456 | 442 |
| Short-term investments | 98 | 121 |
| Cash and cash equivalents | 108 | 296 |
| Total current assets | 1,045 | 903 |
| Total assets | 13,501 | 22,972 |
| of which, interest-bearing assets | 523 | 484 |
| Equity and liabilities | ||
| Total equity | 13,484 | 22,944 |
| Provisions | 0 | 0 |
| Non-current liabilities | 2 | 3 |
| Current liabilities | 15 | 25 |
| Total liabilities | 17 | 28 |
| Total equity and liabilities | 13,501 | 22,972 |
| of which, interest-bearing liabilities | 3 | 4 |
Statement of changes in equity
| Q4 | Q4 | Full year | Full year | |
|---|---|---|---|---|
| SEK M | 2022 | 2021 | 2022 | 2021 |
| Equity at beginning of period | 11,066 | 21,660 | 22,944 | 16,855 |
| Share-related remuneration LTIP 2022 | 1 | – | 1 | – |
| Issue of class C shares | 1 | – | 1 | – |
| Buyback of class C shares | -1 | – | -1 | – |
| Cash dividend | – | – | -167 | -148 |
| Profit/loss for the period | 2,417 | 1,284 | -9,294 | 6,237 |
| Closing balance, equity | 13,484 | 22,944 | 13,484 | 22,944 |
Statement of cash flows
| Q4 | Q4 | Full year | Full year | |
|---|---|---|---|---|
| SEK M | 2022 | 2021 | 2022 | 2021 |
| Cash flow from operating activities before changes in working capital | -4 | -15 | 169 | 929 |
| Cash flow from changes in working capital | 6 | 13 | -10 | 7 |
| Cash flow from operating activities | 2 | -2 | 159 | 936 |
| Cash flow from investing activities | -9 | -336 | 121 | -1,656 |
| Cash flow from financing activities | 0 | -1 | -168 | -147 |
| Cash flow for the period | -7 | -339 | 112 | -867 |
| Cash and cash equivalents at beginning of period | 415 | 635 | 296 | 1,163 |
| Cash flow for the period | -7 | -339 | 112 | -867 |
| Cash and cash equivalents at end of period | 408 | 296 | 408 | 296 |
Multi-year overview
| Data per share 1) | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Net asset value, SEK2) | 196.3 | 323.2 | 239.6 | 196.6 | 137.1 |
| Share price, SEK | 246.4 | 438.2 | 293.6 | 212.0 | 108.4 |
| Share price as a percentage of net asset value | 125% | 136% | 123% | 108% | 79% |
| Parent Company basic equity per share, SEK | 181.6 | 309.4 | 226.8 | 183.6 | 129.1 |
| Parent Company equity per share excl. buybacks, SEK | 181.9 | 309.4 | 226.8 | 183.6 | 129.8 |
| Group basic equity per share, SEK | 195.9 | 323.1 | 238.7 | 196.8 | 136.5 |
| Group equity per share excl. buybacks, SEK | 196.2 | 323.1 | 238.7 | 196.8 | 137.2 |
| Parent Company basic earnings per share, SEK3) | -125.3 | 84.1 | 45.2 | 55.8 | 23.2 |
| Group basic earnings per share, SEK3) | -124.7 | 85.8 | 45.1 | 61.3 | 26.3 |
| Number of shares, thousands | 74,252 | 74,147 | 74,147 | 68,972 | 69,333 |
| Number of shares excluding share buybacks, thousands | 74,147 | 74,147 | 74,147 | 68,972 | 68,972 |
| Average basic number of shares, thousands | 74,161 | 74,147 | 71,757 | 68,972 | 69,245 |
| Key figures | |||||
| Dividend, SEK per share | 2.25 | 2.0 | 1.0 | 2.0 | 2.0 |
| of which, extraordinary dividend, SEK per share | – | – | – | – | 0.5 |
| Direct return | 0.9% | 0.5% | 0.3% | 0.9% | 1.8% |
| Total return | -43.1% | 50.1% | 39.2% | 97.9% | 12.7% |
| Market capitalisation, SEK M | 18,270 | 32,491 | 21,770 | 14,622 | 7,516 |
| Net asset value, SEK M | 14,559 | 23,964 | 17,763 | 13,563 | 9,454 |
| Return on equity | -48.0% | 31.3% | 22.0% | 35.6% | 19.5% |
| Management expenses/Net asset value | 0.49% | 0.30% | 0.29% | 0.33% | 0.55% |
| Parent Company results and financial position | |||||
| Profit/loss after tax, SEK M | -9,294 | 6,237 | 3,242 | 3,850 | 1,609 |
| Total assets, SEK M | 13,501 | 22,972 | 16,845 | 12,688 | 8,976 |
| Equity, SEK M | 13,484 | 22,944 | 16,819 | 12,662 | 8,950 |
| Equity/assets ratio | 100% | 100% | 100% | 100% | 100% |
| Cash and cash equivalents and short-term investments, SEK M | 506 | 417 | 1,460 | 800 | 461 |
| Consolidated profit and financial position | |||||
| Net sales, SEK M | 0 | 0 | 267 | 382 | 416 |
| Profit/loss after tax, SEK M | -9,235 | 6,362 | 3,236 | 4,229 | 1,821 |
| Total assets, SEK M | 14,643 | 24,004 | 17,935 | 13,786 | 9,624 |
| Equity, SEK M | 14,548 | 23,956 | 17,702 | 13,573 | 9,462 |
| Equity/assets ratio | 99% | 100% | 99% | 98% | 98% |
| Net loan debt (-)/receivable (+), SEK M | 456 | 469 | 1,166 | 648 | 373 |
| Average number of employees | 10 | 9 | 229 | 226 | 234 |
1) All historical data per share have been adjusted for shares in issue with a time-weighting factor as prescribed by IAS 33.
2) Net asset value consists of the market value of Bure's listed and unlisted holdings, short term investments, other net assets and cash and cash equivalents.
3) There was no dilution effect during the periods.
Notes
Note 1 – Accounting policies
Bure applies International Financial Reporting Standards (IFRS) as endorsed for application in the EU. This interim report has been prepared in compliance with IAS 34, Interim Financial Reporting, the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2, Accounting for Legal Entities.
Group consolidation principles
Bure Equity is an investment entity in accordance with IFRS 10 - Investment entity.
An investment company does not consolidate subsidiaries in accordance with IFRS 10 Consolidated Financial Statements and does not apply IFRS 3 Operating Acquisitions with the exception of subsidiaries that are active in investing activities. An investment company values portfolio companies at fair value in accordance with IFRS 9 Financial Instruments.
Since 1 January 2021, the Bure Group consists of the parent company Bure Equity AB, Atle Investment Management AB and Bure Growth AB.
Parent company accounting principles
The parent company's investments in companies and other financial assets are reported at fair value as profit and loss in the same way as for the group.
For further information on accounting and valuation principles, please see Note 1 in the 2021 annual report.
New accounting principles applied from 1 January 2022: revised or amended IFRS standards are not considered to have any significant impact on earnings or balance statements. Bure continuously updates its analysis of upcoming changes.
Note 2 – Segment reporting
All activities in the entity are considered to constitute a single segment.
Note 3 – Effects of changed estimates and assessments
Important estimates and assessments are presented in Note 1 in the 2021 annual report. No changes to these estimates and assessments have been that could have a significant impact on the current interim report.
Note 4 – Financial instruments
Fair value and book value of financial assets and liabilities Fair value has been calculated for all financial assets and liabilities in accordance with IFRS 13. Fair value is estimated to be equal to the book value of accounts receivable and other receivables, other current receivables, cash and other cash and cash equivalents, accounts payable, and other liabilities and borrowing. Book value less write-downs is an estimated fair value for accounts receivable and accounts payable. For long-term non-interest-bearing liabilities, fair value has been calculated by discounting future cash flows with current market interest rates regarding the term of the debt.
The investment entity's financial assets and liabilities are classified in accordance with IFRS 13 in the following three categories
Level 1: Listed prices in an active market for identical assets or liabilities.
- Level 2: Other observable data for the asset or liability other than listed prices included in Level 1, either directly or indirectly.
- Level 3: Data for the asset or liability that are not in their entirety based on observable market data.
Bure reports listed holdings at fair value with changes in value in the income statement (level 1). Bure's listed holdings consist of ACQ Bure AB, Cavotec SA, Mentice AB, Mycronic AB, Ovzon AB, Vitrolife AB, and Xvivo Perfusion AB.
Bure reports unlisted holdings at fair value (level 3). Bure's unlisted holdings consist of Allgon AB, Alcur Fonder AB, AMIP AB, Atle Investment Services AB, BioLamina AB, Fondbolaget Fondita Ab, HealthInvest Partners AB, Mercuri International Group AB, My Driving Academy Sweden AB, ScandiNova Systems AB, Teknik Innovation Norden Fonder AB and Yubico AB.
Bure has chosen to market value all financial assets based on International Private Equity and Venture Capital Valuation Guidelines (IPEV). The guidelines describe a number of methods for determining the fair value of each holding. Considerable emphasis is placed on recently completed market transactions in the company, e.g., share issues or the acquisition of existing shares. Transactions in comparable companies can also be used. Other valuation methods include discounting of forecast cash flows with relevant discount rates and applying valuation multiples such as EV/Sales, EV/EBITDA, EV/EBITA, EV/EBIT, PER and P/AuM which are adjusted to take into account differences in market, business, and risk. In general, a liquidity discount is also applied for unlisted assets. Valuation takes place on an ongoing basis and is published in conjunction with quarterly reports.
Note 4 – Financial instruments (cont.)
Real value hierarchy, Group
| 31 December 2022 | 31 December 2021 | |||||||
|---|---|---|---|---|---|---|---|---|
| SEK M | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total |
| Financial assets | ||||||||
| Financial assets at fair value from the income statement | 11,550 | 55 | 2,422 | 14,027 | 20,932 | 55 | 2,380 | 23,366 |
| Other long-term receivables | 1 | – | 41 | 42 | 1 | – | 145 | 146 |
| Financial investments | 116 | – | – | 116 | 133 | – | – | 133 |
| Total financial assets | 11,667 | 55 | 2,463 | 14,185 | 21,065 | 55 | 2,526 | 23,645 |
| Financial liabilities | ||||||||
| Leasing liabilities | – | – | 3 | 3 | – | – | 4 | 4 |
| Other long-term liabilities | 1 | – | 51 | 52 | 1 | – | – | 1 |
| Accrued expenses and prepaid income | – | – | 11 | 11 | – | – | 21 | 21 |
| Total financial liabilities | 1 | – | 65 | 66 | 1 | – | 25 | 26 |
Valuation of unlisted assets at 31 December 2022
| SEK M | Holding | Group book value | Valuation model |
|---|---|---|---|
| Holdings in Bure Equity AB | |||
| Allgon AB and AMIP AB | 91.1% / 14.5% | 753 | EV/EBIT, PER |
| Mercuri International Group AB | 90.4% | 68 | EV/EBIT, DCF |
| Holdings in Atle Investment Management AB | 256 | ||
| Alcur Fonder AB | 30.4% | P/AuM | |
| Atle Investment Services AB | 100.0% | Book value of equity | |
| Fondbolaget Fondita Ab | 20.1% | P/AuM, EV/EBIT | |
| HealthInvest Partners AB | 45.8% | Accrued acquisition value | |
| Teknik Innovation Norden Fonder AB | 35.2% | P/AuM | |
| Holdings in Bure Growth AB | 1,362 | ||
| BioLamina AB | 46.5% | Latest transaction | |
| My Driving Academy Sweden AB | 30.4% | Latest transaction, DCF | |
| ScandiNova Systems AB | 27.9% | Latest transaction | |
| Yubico AB | 17.6% | Latest transaction, EV/Sales |
Valuation of unlisted assets at 31 december 2021
| SEK M | Holding | Group book value | Valuation model |
|---|---|---|---|
| Holdings in Bure Equity AB | |||
| Allgon AB and AMIP AB | 100.0% / 100.0% | 746 | Accrued acquisition value |
| Mercuri International Group AB | 90.4% | 98 | EV/EBIT, DCF |
| Investment AB Bure | 100.0% | 63 | Book value of equity |
| Holdings in Atle Investment Management AB | 171 | ||
| Alcur Fonder AB | 30.9% | P/AuM | |
| Atle Investment Services AB | 100.0% | Book value of equity | |
| Fondbolaget Fondita Ab | 20.1% | P/AuM, EV/EBIT | |
| Teknik Innovation Norden Fonder AB | 37.1% | P/AuM | |
| Holdings in Bure Growth AB | 1,302 | ||
| BioLamina AB | 44.5% | Latest transaction | |
| My Driving Academy Sweden AB | 25.1% | Latest transaction, DCF | |
| ScandiNova Systems AB | 27.8% | Latest transaction | |
| Yubico AB | 17.8% | Latest transaction |
Not 5 – Classification of financial instruments
| Group 31 December 2022 SEK M |
Financial assets and liabilities valued at fair value from income statements |
Financial assets valued at accrued acquisition value |
Liabilities and customer receivables and other liabilities valued at accrued acquisition value |
Total carrying amount |
|---|---|---|---|---|
| Financial assets | ||||
| Financial assets valued at fair value from the income statements |
14,027 | – | – | 14,027 |
| Other long-term receivables | – | – | 42 | 42 |
| Other short-term receivables | – | – | 4 | 4 |
| Financial investments | 116 | – | – | 116 |
| Cash and bank balances | – | 416 | – | 416 |
| Total financial assets | 14,144 | 416 | 45 | 14,605 |
| Financial liabilities | ||||
| Leasing liabilities | – | – | 3 | 3 |
| Other long-term liabilities | – | – | 52 | 52 |
| Other non-interest-bearing liabilities | – | – | 21 | 21 |
| Total financial liabilities | – | – | 76 | 76 |
| Financial assets and liabilities valued at fair value from income statements |
Financial assets valued at accrued acquisition value |
Liabilities and customer receivables and other liabilities valued at accrued acquisition value |
Total carrying amount |
|---|---|---|---|
| 23,366 | – | – | 23,366 |
| – | – | 146 | 146 |
| – | – | 7 | 7 |
| 133 | – | – | 133 |
| – | 326 | – | 326 |
| 23,499 | 326 | 153 | 23,978 |
| Leasing liabilities | – | – | 4 | 4 |
|---|---|---|---|---|
| Other long-term liabilities | – | – | 1 | 1 |
| Other non-interest-bearing liabilities | – | – | 26 | 26 |
| Total financial liabilities | – | – | 31 | 31 |
Note 6 – Financial position
Net loan receivable: Cash and cash equivalents, interest-bearing investments and interest-bearing current and non-current receivables minus interest-bearing current and non-current liabilities.
| Group, SEK M | 31 December 2022 | 31 December 2021 |
|---|---|---|
| Cash and cash equivalents | 416 | 326 |
| Current interest-bearing receivables | 2 | 3 |
| Non-current interest-bearing receivables | 41 | 145 |
| Interest-bearing assets | 459 | 474 |
| Current interest-bearing leasing liabilities | 2 | 2 |
| Non-current interest-bearing leasing liabilities | 1 | 2 |
| Interest-bearing liabilities | 3 | 4 |
| Net receivable at end of the year | 456 | 469 |
| Parent Company, SEK M | 31 December 2022 | 31 December 2021 |
|---|---|---|
| Cash and cash equivalents | 408 | 296 |
| Current interest-bearing receivables | 83 | 44 |
| Non-current interest-bearing receivables | 33 | 145 |
| Interest-bearing assets | 523 | 484 |
| Current interest-bearing leasing liabilities | 2 | 2 |
| Non-current interest-bearing leasing liabilities | 1 | 2 |
| Interest-bearing liabilities | 3 | 4 |
| Net receivable at end of the year | 520 | 480 |
Bure Equity finances operations in Atle Investment Management and Bure Growth with equity and loans. The table below presents internal loans in the Bure Group.
| Internal receivables within the Group | |||
|---|---|---|---|
| SEK M | 31 December 2022 | 31 December 2021 | |
| Atle Investment Management | 81 | 41 | |
| Bure Growth | 449 | 436 | |
| Total | 531 | 477 |
Note 7 – Issued securities and contingent liabilities
As of December 31 2022, the investment entity had not issued any securities and had not entered into contingent liabilities.
Definitions
Basic earnings per share
Profit/loss after tax divided by the average number of shares outstanding during the year. For the Group, net profit less the non-controlling interests' share in profit for the year.
Diluted earnings per share
Profit after tax divided by the average number of shares outstanding during the year after dilution. For the Group, net profit less non-controlling interests' share in profit for the year. The average number of shares after full dilution is calculated according to the rules in IFRS, IAS 33 Earnings per Share.
Earnings per share
Earnings after tax divided by the average number of outstanding shares during the period. For the parent company, net earnings is used less the minority share of earnings for the period.
The average number of shares after dilution is calculated according to IFRS regulation, IAS 33 Earnings per share.
EBIT
Operating profit after amortization of goodwill/acquisition-related surplus values and amortization of fixed assets.
Equity per share
Equity divided by the number of shares outstanding. As of the transition to IFRS on 1 January 2005, non-controlling interests are included in total equity.
Equity/asset ratio
Equity in relation to total assets. As of the transition to IFRS on 1 January 2005, non-controlling interests are included in total equity.
Growth
Increase in net sales in relation to net sales for the previous year. The key figure thus includes both organic and acquisition-driven growth.
IRR
Internal Rate of Return.
Management costs/net asset value
Management costs during the period divided by net asset value at the end of the period.
Market capitalization
Share price multiplied by the total number of shares outstanding.
Net asset value
Market value, (valued at fair value), of Bure's listed and unlisted holdings and short-term investments plus accrued acquisition value of other net assets and cash and cash equivalents.
Net loan liability
Same definition as net loan receivable, but is used when interest-bearing liabilities exceed interest-bearing assets.
Net loan receivable
Financial interest-bearing assets minus interest-bearing liabilities.
Return on equity
Profit/loss after tax divided by average equity.
Share buyback
For several years, Swedish companies have been permitted to repurchase up to 10 per cent of their own outstanding shares, provided that this is approved by the Annual General Meeting within the framework of non-restricted equity.
Total return
The total of the year's share price growth and reinvested dividends divided by the share price at the beginning of the year.
This is Bure
Bure is a listed investment company that is quoted on Nasdaq Stockholm Large Cap. On 31 December 2022 the portfolio consisted of twelve companies, of which seven are listed holdings.
Our business concept is to be a long-term principal owner of operating companies. Through far-reaching engagement and value-driving initiatives and activities, we support the portfolio companies in becoming successful in their respective businesses.
Our objective is to create a long-term sustainable total return for our shareholders and to be a competitive investment alternative in the market.
Bure's strategic cornerstones are:
- Long-term approach
- Commitment and responsibility
- Adapted leadership
- Financial strength
Financial calendar
Annual General Meeting 3 May 2023 Interim report January – March 9 May 2023 Interim report January – June 18 August 2023 Interim report January – September 9 November 2023 Year-end report 2023 22 February 2024
For information contact
Henrik Blomquist, CEO: +46 8 614 00 20 Max Jonson, CFO: +46 8 614 00 20